{"created":"2023-06-19T09:04:44.159628+00:00","id":97,"links":{},"metadata":{"_buckets":{"deposit":"496c9098-ea8c-42db-8769-8aa83d21ee94"},"_deposit":{"created_by":14,"id":"97","owners":[14],"pid":{"revision_id":0,"type":"depid","value":"97"},"status":"published"},"_oai":{"id":"oai:nvlu.repo.nii.ac.jp:00000097","sets":["1:21"]},"author_link":["98"],"item_10002_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2014-12","bibliographicIssueDateType":"Issued"},"bibliographicPageEnd":"22","bibliographicPageStart":"12","bibliographicVolumeNumber":"63","bibliographic_titles":[{"bibliographic_title":"日本獣医生命科学大学研究報告"}]}]},"item_10002_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"1980 年代にヒトのインスリンや成長ホルモンが遺伝子組換え大腸菌から得られるようになった。しかし，この生産システムはこれらのホルモン以外の生理活性物質に適用するには限界がある。細菌は，高次構造をもつタンパク質を構築できない。これまでに，酵母，植物，昆虫，ニワトリなどを宿主とした生産システムが開発されてきたが，生理活性物質の生産に利用するには限界がある。現在，トランスジェニック（Tg）家畜の乳汁中にヒトの生理活性物質を分泌させる生産システムが注目されている。2006 年にEAEM（欧州医薬品評価庁）がTg ヤギの乳汁から得たヒトアンチトロンビンⅢを世界で最初の医薬品として認可した。この生産システムには，未だ改善すべき課題はあるものの，将来多くの関連企業が参入してくることが予想される。\n","subitem_description_type":"Abstract"}]},"item_10002_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"18827314","subitem_source_identifier_type":"ISSN"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"東條, 英昭"}],"nameIdentifiers":[{"nameIdentifier":"98","nameIdentifierScheme":"WEKO"},{"nameIdentifier":"1000020041668","nameIdentifierScheme":"NRID","nameIdentifierURI":" "}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2016-06-09"}],"displaytype":"simple","filename":"東條英昭.pdf","filesize":[{"value":"2.4 MB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"PDF","url":"https://nvlu.repo.nii.ac.jp/record/97/files/東條英昭.pdf"},"version_id":"73c48e13-c52b-465d-8384-fb45d09dde08"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"トランスジェニック家畜","subitem_subject_scheme":"Other"},{"subitem_subject":"組換えタンパク質","subitem_subject_scheme":"Other"},{"subitem_subject":"医薬品","subitem_subject_scheme":"Other"},{"subitem_subject":"transgenic farm animals","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"recombinant proteins","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"biomedicines","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"トランスジェニック家畜を利用した生理活性物質生産システムの現状と展望","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"トランスジェニック家畜を利用した生理活性物質生産システムの現状と展望"},{"subitem_title":"Current Status and Prospects for Biomedicines Produced in Transgenic Farm Animals","subitem_title_language":"en"}]},"item_type_id":"10002","owner":"14","path":["21"],"pubdate":{"attribute_name":"公開日","attribute_value":"2016-06-09"},"publish_date":"2016-06-09","publish_status":"0","recid":"97","relation_version_is_last":true,"title":["トランスジェニック家畜を利用した生理活性物質生産システムの現状と展望"],"weko_creator_id":"14","weko_shared_id":-1},"updated":"2023-06-19T09:10:17.233172+00:00"}